Mizukami Kazuhiro, Katsuta Makoto, Okamoto Kazuhisa, Fukuda Kensuke, Ogawa Ryo, Kawahara Yoshinari, Hirashita Yuka, Sato Yuto, Fukuda Masahide, Okimoto Tadayoshi, Kodama Masaaki, Fujioka Toshio, Murakami Kazunari
Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita 879-5593, Japan.
Department of Internal Medicine, Takada Chuo Hospital, 1176-1 Shinchi, Bungotakada, Oita 879-0627, Japan.
J Clin Biochem Nutr. 2020 Nov;67(3):332-337. doi: 10.3164/jcbn.20-17. Epub 2020 Jun 30.
The infection and functional dyspepsia are often coexisted. The effect of acotiamide, a drug for functional dyspepsia, on the result of diagnosis has yet to be studied. We evaluated the influence of acotiamide on the results of diagnosis in the C-urea breath test. Twenty patients with -positive functional dyspepsia were treated with 100 mg of acotiamide three times a day for two weeks. Changes in C-urea breath test were investigated before and after administration, and two weeks after administration as the follow-up period. The C-urea breath test and the medical questionnaire of modified frequency scale for the symptoms of gastroesophageal reflux disease were conducted at every period. Nineteen patients were included for analysis. No patients showed negative in C-urea breath test at Weeks 2 and 4. On the symptom scale, dyspepsia and total scores decreased from Week 0 to Week 2 and increased from Week 2 to Week 4, and the improvement rates of the dyspepsia score at Week 2 was 63%. In conclusion, we confirmed that acotiamide is unlikely to influence the result of C-urea breath test and it may improve the symptoms of functional dyspepsia during eradication treatment.
感染与功能性消化不良常并存。用于治疗功能性消化不良的药物阿考替胺对诊断结果的影响尚未得到研究。我们评估了阿考替胺对碳-尿素呼气试验诊断结果的影响。20例功能性消化不良阳性患者接受阿考替胺100毫克,每日三次,治疗两周。在给药前后以及给药后两周随访期调查碳-尿素呼气试验的变化。在每个阶段都进行碳-尿素呼气试验和改良的胃食管反流病症状频率量表的医学问卷调查。纳入19例患者进行分析。在第2周和第4周,没有患者的碳-尿素呼气试验呈阴性。在症状量表上,消化不良和总分从第0周降至第2周,并从第2周升至第4周,第2周消化不良评分的改善率为63%。总之,我们证实阿考替胺不太可能影响碳-尿素呼气试验的结果,并且在根除治疗期间可能改善功能性消化不良的症状。